Phase 3
Completed N=912
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Source: ClinicalTrials.gov NCT03607422 ↗Enrolled (actual)
912
Serious AEs
8.8%
Results posted
Mar 2022
Primary outcomePrimary: Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 — 13.3; 60.1; 72.9 percentage of participants — p=<0.001
◆ Published Evidence
Emerging
15citations · ~15 / year
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
Summary
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Linked Publications (5)
-
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
-
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.
-
Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.
-
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2).
-
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 |
13.3; 60.1; 72.9 | <0.001 sig |
| PRIMARY Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 |
4.7; 38.8; 52.0 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16 |
9.1; 41.9; 59.6 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16 |
5.4; 42.4; 58.5 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4 |
3.6; 48.9; 60.7 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2 |
3.6; 33.0; 44.0 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1 |
0.7; 7.4; 15.7 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2 |
0.7; 7.4; 7.9 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3 |
3.0; 11.5; 17.3 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period |
24.5; 2.2; 1.4 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16 |
12.4; 50.2; 62.3 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16 |
13.4; 49.4; 65.1 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16 |
12.7; 53.0; 66.2 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16 |
16.7; 57.0; 71.5 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16 |
18.9; 57.0; 69.5 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16 |
0.7; 14.1; 18.8 | <0.0001 sig |
| SECONDARY Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16 |
-17.04; -51.20; -66.49 | <0.001 sig |
| SECONDARY Main Study: Percent Change From Baseline in EASI Score at Week 16 |
-34.51; -74.13; -84.65 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16 |
28.7; 70.9; 83.5 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 |
28.4; 71.7; 77.6 | <0.001 sig |
| SECONDARY Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16 |
-28.43; -57.90; -68.44 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16 |
11.4; 46.0; 56.1 | <0.001 sig |
| SECONDARY Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16 |
4.7; 23.8; 37.9 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16 |
13.3; 69.0; 73.4 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 |
5.0; 44.8; 59.4 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16 |
3.4; 38.2; 56.7 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16 |
1.7; 48.3; 62.0 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4 |
3.4; 38.2; 50.0 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2 |
6.7; 37.9; 53.2 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1 |
0.0; 12.7; 5.0 | 0.075 |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2 |
0.0; 8.9; 3.2 | 0.151 |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3 |
1.7; 14.3; 9.7 | 0.008 sig |
| SECONDARY Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period |
20.0; 1.7; 1.6 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16 |
9.5; 37.5; 61.4 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16 |
7.5; 39.6; 60.8 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16 |
10.9; 47.9; 60.0 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16 |
18.0; 60.0; 72.0 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16 |
22.4; 52.5; 68.0 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16 |
1.7; 15.5; 19.4 | <0.001 sig |
| SECONDARY Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16 |
-11.02; -47.56; -66.95 | <0.001 sig |
| SECONDARY Adolescents: Percent Change From Baseline in EASI Score at Week 16 |
-42.19; -77.85; -84.81 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16 |
28.1; 66.1; 80.7 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16 |
19.2; 68.2; 73.3 | <0.001 sig |
| SECONDARY Adolescents: Percent Change From Baseline in SCORAD Score at Week 16 |
-27.91; -57.89; -72.81 | <0.001 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16 |
16.0; 37.5; 43.8 | 0.016 sig |
| SECONDARY Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16 |
7.7; 13.6; 46.9 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age
- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria
- Active moderate to severe AD defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, body surface area (BSA) affected by AD ≥ 10%, and weekly average of daily Worst Pruritus numerical rating scale (NRS) score ≥ 4.
- Candidate for systemic therapy or have recently required systemic therapy for AD
- Documented history (within 6 months prior to Baseline) of inadequate response to topical corticosteroid (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD or for whom topical treatments are otherwise medically inadvisable due to side effects or safety risks
Exclusion Criteria
- Prior exposure to any Janus kinase (JAK) inhibitor
- Unable or unwilling to discontinue current AD treatments prior to the study
- Requirement of prohibited medications during the study
- Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Data sourced from ClinicalTrials.gov (NCT03607422) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.